Clinical Trial Update: Ototoxicity of Artemether / Lumefantrine (Coartem) and Other Antimalarials [Phase 4]

View source ↗

Summary

A Phase 4 safety update examining potential ototoxicity risks of artemether/lumefantrine (Coartem) and other antimalarials in malaria patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• Coartem (artemether-lumefantrine)
• Other antimalarials

Snippet

Sponsor: Jimma University | Conditions: Malaria | Phase 4 | Status: COMPLETED